<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004065</url>
  </required_header>
  <id_info>
    <org_study_id>5051-201</org_study_id>
    <secondary_id>2019-000601-77</secondary_id>
    <nct_id>NCT04004065</nct_id>
  </id_info>
  <brief_title>Study for Dose Determination of SRP-5051, Then Dose Expansion in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment</brief_title>
  <acronym>MOMENTUM</acronym>
  <official_title>A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, Then Dose Expansion, in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be comprised of 2 parts: 1) Part A (Multiple Ascending Dose [MAD]) will be&#xD;
      conducted to evaluate the safety and tolerability of SRP-5051 at multiple ascending dose&#xD;
      levels to determine the maximum tolerated dose (MTD), and 2) Part B (Dose Expansion) will be&#xD;
      conducted to evaluate SRP-5051 administered at the MTD determined in Part A or, if&#xD;
      applicable, at a second dose introduced in Part B. Patients enrolling in Part B will be those&#xD;
      who completed Part A as well as additional expansion cohort patients who will enroll at the&#xD;
      beginning of Part B.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Incidence of Adverse Events (AEs)</measure>
    <time_frame>Part A: approximately 68 weeks</time_frame>
    <description>Incidence of adverse events includes clinically significant laboratory abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline in Dystrophin Protein Level</measure>
    <time_frame>Baseline, Week 12 or Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacokinetics (PK): Plasma Concentration of SRP-5051</measure>
    <time_frame>Pre-dose and at multiple time points (up to 32 hours) after end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: PK: Urine Concentration of SRP-5051</measure>
    <time_frame>Pre-dose and at multiple time periods (up to 48 hours) after end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Exon-Skipping Levels</measure>
    <time_frame>Baseline, Week 12 or Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Incidence of Adverse Events (AEs)</measure>
    <time_frame>Part B: approximately 44 weeks</time_frame>
    <description>Incidence of adverse events includes clinically significant laboratory abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Forced Vital Capacity (FVC) (percent predicted)</measure>
    <time_frame>Baseline, Week 12 or Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in the North Star Ambulatory Assessment (NSAA)</measure>
    <time_frame>Baseline, Week 12 or Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in the Performance of Upper Limb (PUL) Scores</measure>
    <time_frame>Baseline, Week 12 or Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in the Brooke Upper Extremity Scale score (Brooke score)</measure>
    <time_frame>Baseline, Week 12 or Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: PK: Plasma Concentration of SRP-5051</measure>
    <time_frame>Part B predose and at multiple timepoints (up to 24 hours) after end of infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Part A: SRP-5051</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be sequentially assigned to receive 1 of the 5 escalating dose levels of SRP-5051, monthly, via intravenous (IV) infusion for at least 12 weeks during Part A. Once the maximum tolerated dose (MTD) has been determined in Part A, all patients who have completed Part A will transition to Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: SRP-5051</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive SRP-5051 at the MTD determined in Part A, or if applicable, at a second dose introduced in Part B, monthly, via IV infusion, for 24 weeks. This includes the patients who roll over from Part A, as well as expansion cohort patients who will enroll in the study at the beginning of Part B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-5051</intervention_name>
    <description>SRP-5051 injection, for IV use</description>
    <arm_group_label>Part A: SRP-5051</arm_group_label>
    <arm_group_label>Part B: SRP-5051</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a genetic diagnosis of DMD and an out-of-frame deletion mutation of the DMD gene&#xD;
             amenable to exon 51-skipping treatment.&#xD;
&#xD;
          -  Has been on a stable dose of oral corticosteroids for at least 12 weeks prior to study&#xD;
             drug administration, or has not received corticosteroids for at least 12 weeks prior&#xD;
             to study drug administration.&#xD;
&#xD;
          -  Part A age group (ages 7 to 21)&#xD;
&#xD;
          -  Part B age group (ages 4 to 21)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a left ventricular ejection fraction (LVEF) less than (&lt;) 40.0 percent (%) based&#xD;
             on an echocardiogram (ECHO) performed within 12 weeks prior to Screening or at the&#xD;
             Screening visit.&#xD;
&#xD;
          -  Has a FVC &lt; 40.0% of predicted value within 12 weeks prior to Screening or at&#xD;
             Screening.&#xD;
&#xD;
          -  Initiation or change of dosing (except for modifications to accommodate changes in&#xD;
             weight or changes in standard of care) within 12 weeks prior to Screening for any of&#xD;
             the following: angiotensin-converting enzyme inhibitors, angiotensin receptor-blocking&#xD;
             agents, Î²-blockers, or potassium.&#xD;
&#xD;
          -  Initiation or change of dosing within 12 weeks prior to Screening for over-the-counter&#xD;
             preparations, such as herbal/nonherbal supplements, vitamins, minerals, and&#xD;
             homeopathic preparations.&#xD;
&#xD;
          -  Treatment with any exon 51-skipping therapy within 12 weeks prior to Screening, or&#xD;
             with any experimental gene therapy for the treatment of DMD at any time.&#xD;
&#xD;
        Other inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest Florida Clinical Research Group, LLC</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Neuromuscular Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - London Health Sciences Centre (LHSC)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de DÃ©u. U.B.</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>Duchenne</keyword>
  <keyword>Dystrophy</keyword>
  <keyword>Dystrophin</keyword>
  <keyword>Exon Skipping</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Exon 51</keyword>
  <keyword>Nonambulatory</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

